The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

Two bills heard in a state Senate committee are designed to lower prices, provide fair competition for independent pharmacies ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...